Research ProgramsNew IMP ProductsOur main area of research is on new applications of Immutep's soluble recombinant LAG-3 proteins (technology "ImmuFact®"), LAG-3 fusion proteins (technology "ImmuCcine®") and LAG-3-specific chimeric monoclonal antibodies (technology "ImmuTune®"). © 2002 Immutep, S.A.
|
Press Release
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
Immutep S.A. announced today that the final results from its Phase ...
01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer 
Immutep S.A. announced today the final results from its Phase I/II ...
10/2009 - New results confirm that ImmuFact IMP321 doubles clinical response rate 
Immutep S.A. announced today interim results from the first three ...
09/2009 - Clinical research paper describes IMP321’s potency in inducing progression-free survival improvement and effector memory T cells 
Immutep S.A. announced today the publication of a clinical research ...
04/2009 - A Phase I clinical trial of ImmuFact IMP321 in pancreatic cancer has started at Washington University in Saint Louis (MO) 
Immutep S.A. announced today the first administration of IMP321 in ...
|
|
